Trial Profile
Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 May 2018
Price :
$35
*
At a glance
- Drugs Florbenazine F18 (Primary)
- Indications Parkinsonian disorders
- Focus Diagnostic use
- 28 May 2016 Planned primary completion date changed from 1 Jul 2016 to 1 May 2016.
- 11 Jul 2014 New trial record